A new study examined organizational differences of whole-brain networks between MS and NMOSD in a prospective cohort of patients with CNS demyelinating disease. All 144 study participants, including ...

The FDA has approved Soliris (eculizumab; Alexion Pharmaceuticals, Inc) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody ...

Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...

Neuromyelitis optica spectrum disorder (NMOSD) is neuroinflammatory disease characterized by optic neuritis and myelitis with presence of anti-aquaporin-4 (AQP4) antibodies. Satralizumab is an anti-IL ...

Transverse myelitis in a patient with neuromyelitis optica spectrum disorder Three agents were recently FDA approved for NMOSD in adults who are AQP4 antibody positive: eculizumab, inebilizumab-cdon, ...

Please provide your email address to receive an email when new articles are posted on . In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its ...

Twenty NMOSD patients representing the general patient population were convened to discuss their employment experiences. Participants reported employment issues due to high disease burdens, a lack of ...

The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that mostly affects your eyes and spinal cord. Your immune system attacks a specific protein, called aquaporin-4 (AQP4). The ...

DelveInsight projects strong NMOSD market growth in the 7MM through 2032, fueled by disease-modifying therapies and key approvals. Leading NMOSD companies include RemeGen, Alexion, Reistone Biopharma, ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...